Enlivex Ltd. develops quality longevity therapeutics and operates a prediction markets treasury alongside its clinical programs. The company’s news centers on Allocetra™, a clinical-stage immunotherapy for inflammatory conditions associated with aging, with a primary focus on moderate-to-severe age-related knee osteoarthritis.
Recurring updates also cover the RAIN token and Rain protocol, including digital asset treasury holdings, exchange listings, decentralized prediction-market infrastructure, tokenized exposure to Enlivex ordinary shares, financial results affected by treasury assets, financing activity, and share repurchase authorization.
Enlivex Therapeutics (Nasdaq: ENLV) will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 8:00 AM ET.
A live webcast of the presentation can be accessed here.
Enlivex specializes in developing immunotherapy solutions aimed at rebalancing the immune system for severe conditions without approved treatments, including Cytokine Release Syndrome and solid tumors.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has initiated a multi-center Phase II clinical trial for Allocetra in COVID-19 patients, following promising results in a prior Phase Ib trial for sepsis. The trial aims to assess the safety and efficacy of Allocetra in addressing cytokine storms and organ dysfunction associated with severe COVID-19 symptoms. Up to five patients will be recruited per center, with primary endpoints including changes in PaO2/FiO2 ratio and adverse events. The study runs independently of an upcoming Phase IIb trial for sepsis planned for late 2020.